The miR-138-5p/MYH9 axis boosted cisplatin resistance and decreased immune response in cancer cells in non-small cell lung cancer (NSCLC) (Xu et al., 2021; Wang S. et al., 2022). Here, MYH9 is linked to non-small cell lung carcinoma.